{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:18:17Z","timestamp":1787833097556,"version":"build-2784847793"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Radiation-induced lung injury (RILI) remains a major dose-limiting toxicity of thoracic radiotherapy. In the era of combination anticancer therapy, its recognition and management have become more difficult. Systemic treatments can cause pneumonitis or interstitial lung disease on their own, but they can also change how radiation injury evolves. By sustaining inflammation or delaying repair of the irradiated lung, these agents may convert a typical radiation-related injury into a more complex pulmonary event. For this reason, post-treatment lung injury should not be interpreted solely by radiation dose or systemic therapy exposure. A RILI-centered approach may provide a clinically useful framework, allowing pulmonary events to be viewed as radiation-dominant RILI, interaction-modified RILI, or non-radiation mimics. In this narrative review, we summarize the pathological continuum of RILI, discuss how systemic therapies and treatment sequence influence its clinical expression, and outline a practical framework for diagnosis and management in combined-treatment settings. We also present a toxicity grade\u2013based, attribution-informed management approach, ranging from observation and corticosteroid treatment to multidisciplinary care and selective immunosuppressive escalation for severe or steroid-refractory events. Antifibrotic strategies are considered separately for progressive fibrotic injury, alongside individualized decisions regarding systemic therapy interruption or rechallenge. This perspective may help clinicians balance pulmonary safety with the therapeutic benefits of modern combined-modality cancer treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1926641","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:25:02Z","timestamp":1787829902000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiation-induced lung injury in the era of combination anticancer therapy: a narrative review"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiuqiong","family":"Chen","sequence":"first","affiliation":[{"name":"Cancer Center of Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Duan","sequence":"additional","affiliation":[{"name":"Cancer Center of Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Xiao","sequence":"additional","affiliation":[{"name":"Cancer Center of Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengbo","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Center of Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Cancer Center of Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Center of Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxia","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Center of Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.110837","article-title":"Diagnosis and treatment of radiation induced pneumonitis in patients with lung cancer: An estro clinical practice guideline","volume":"207","author":"Ruysscher","year":"2025","journal-title":"Radiotherapy Oncol J Eur Soc For Ther Radiol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-328","article-title":"Clinical predictors of severe radiation pneumonitis in patients undergoing thoracic radiotherapy for lung cancer","volume":"13","author":"Yan","year":"2024","journal-title":"Trans Lung Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/mp.15451","article-title":"Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by ct radiomics and machine learning","volume":"49","author":"Cheng","year":"2022","journal-title":"Med Phys"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2025-292","article-title":"Expert consensus on cancer treatment-related lung injury","volume":"17","author":"Lin","year":"2025","journal-title":"J Thorac Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111489","article-title":"Distinguishing immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis by ct radiomics features in non-small cell lung cancer","volume":"128","author":"Wang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.110910","article-title":"Esmo-estro framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy","volume":"208","author":"van Aken","year":"2025","journal-title":"Radiotherapy Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2023.100892","article-title":"Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis - the challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging","volume":"39","author":"Guberina","year":"2023","journal-title":"Neoplasia (New York NY)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6268","article-title":"Pulmonary toxicity generated from radiotherapeutic treatment of thoracic Malignancies","volume":"14","author":"Deng","year":"2017","journal-title":"Oncol Lett"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.984364","article-title":"Modulators of radiation-induced cardiopulmonary toxicities for non-small cell lung cancer: Integrated cytokines, single nucleotide variants, and hbp systems imaging","volume":"12","author":"Mukai-Sasaki","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/hp.0000000000001601","article-title":"Radiation-induced cell death and its mechanisms","volume":"123","author":"Jiao","year":"2022","journal-title":"Health Phys"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rry067","article-title":"Cytokines and radiation-induced pulmonary injuries","volume":"59","author":"Lierova","year":"2018","journal-title":"J Radiat Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: Expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.774807","article-title":"Crossed pathways for radiation-induced and immunotherapy-related lung injury","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13900","article-title":"Radiation versus immune checkpoint inhibitor associated pneumonitis: Distinct radiologic morphologies","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist"},{"key":"B15","article-title":"A phase i study of gemcitabine with concurrent radiotherapy in stage iii, locally advanced non-small cell lung cancer","volume":"9","author":"van Putten","year":"2003","journal-title":"Clin Cancer Res Off J Am Assoc For Cancer Res"},{"key":"B16","article-title":"Gemcitabine induces radiosensitization through inhibition of rad51-dependent repair for dna double-strand breaks","volume":"35","author":"Kobashigawa","year":"2015","journal-title":"Anticancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.02.059","article-title":"Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer","volume":"76","author":"McCurdy","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx009","article-title":"Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage iii non-small cell lung cancer: A multicenter randomized phase iii trial","volume":"28","author":"Liang","year":"2017","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-07-5143","article-title":"Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin b12 in previously treated patients with non-small cell lung cancer","volume":"14","author":"Ohe","year":"2008","journal-title":"Clin Cancer Res Off J Am Assoc For Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyx010","article-title":"Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma\/non-small cell lung cancer)","volume":"47","author":"Tomii","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.4_MeetingAbstracts.447S-a","article-title":"Vinorelbine induced interstitial pneumonitis: A case report","volume":"128","author":"Vats","year":"2005","journal-title":"Chest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1200\/jco.1984.2.5.396","article-title":"Chemotherapy-induced interstitial pneumonitis during treatment of small cell anaplastic lung cancer","volume":"2","author":"Zimmerman","year":"1984","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.09.009","article-title":"Treatment-related pneumonitis of egfr tyrosine kinase inhibitors plus thoracic radiation therapy in patients with non-small cell lung cancer: A systematic review and meta-analysis","volume":"118","author":"Meng","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13816","article-title":"Clinical outcomes and radiation pneumonitis after concurrent egfr-tyrosine kinase inhibitors and radiotherapy for unresectable stage iii non-small cell lung cancer","volume":"12","author":"Xu","year":"2021","journal-title":"Thorac Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage iii EGFR-mutated nsclc","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.lungcan.2019.04.015","article-title":"The incidence of alk inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis","volume":"132","author":"Suh","year":"2019","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5913","article-title":"Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta-analysis","volume":"12","author":"Qie","year":"2023","journal-title":"Cancer Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1339505","article-title":"Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: A retrospective, pharmacovigilance study using the faers database","volume":"15","author":"Hu","year":"2024","journal-title":"Front Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13096","article-title":"Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis","volume":"107","author":"Goto","year":"2016","journal-title":"Cancer Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000019878","article-title":"Tracheoesophageal fistula associated with bevacizumab after thoracic radiotherapy in non-small cell lung cancer: A case report","volume":"99","author":"Zhang","year":"2020","journal-title":"Medicine"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage iii non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226x.2025.42384","article-title":"Rising incidence of radiation pneumonitis after adjuvant durvalumab in nsclc patients treated with concurrent chemoradiotherapy","volume":"64","author":"Stoffers","year":"2025","journal-title":"Acta Oncol (Stockholm Sweden)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage iii non-small cell lung cancer: The phase 2 keynote-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage iii non-small cell lung cancer: The phase iii pacific-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2024.2718","article-title":"Neutrophil-to-lymphocyte ratio reflects lung injury in thoracic radiotherapy and immune checkpoint inhibitors combination therapy with different sequences","volume":"20","author":"Tong","year":"2024","journal-title":"Mol Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110040","article-title":"Dosimetric predictors of radiation pneumonitis in patients with prior immunotherapy exposure: A multi-institutional analysis","volume":"190","author":"Bi","year":"2024","journal-title":"Radiotherapy Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(83)90235-3","article-title":"Lung damage in mice from cyclophosphamide and thoracic irradiation: The effect of timing","volume":"9","author":"Collis","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2004.05.004","article-title":"Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation","volume":"72","author":"R\u00fcbe","year":"2004","journal-title":"Radiotherapy Oncol J Eur Soc For Ther Radiol Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1272\/jnms.75.96","article-title":"Effects of gefitinib on radiation-induced lung injury in mice","volume":"75","author":"Wang","year":"2008","journal-title":"J Nippon Med School = Nippon Ika Daigaku Zasshi"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2152\/jmi.59.174","article-title":"Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats","volume":"59","author":"Miyake","year":"2012","journal-title":"J Med Invest JMI"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01296-y","article-title":"Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model","volume":"124","author":"Jiang","year":"2021","journal-title":"Br J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-838","article-title":"Pd-1 restrains il-17a production from \u03b3\u03b4 t cells to modulate acute radiation-induced lung injury","volume":"10","author":"Sheng","year":"2021","journal-title":"Trans Lung Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2023.149334","article-title":"Regulatory role of rgmb in lung injury promoted by the combination of carbon ion irradiation and anti-pd-1 antibody through erk1\/2 and p38 mapk pathways","volume":"691","author":"Feng","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s350112","article-title":"Effect of pd-1 inhibitor combined with x-ray irradiation on the inflammatory microenvironment and lung tissue injury in mice","volume":"15","author":"Geng","year":"2022","journal-title":"J Inflammation Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1177\/15593258251322324","article-title":"Comparative analysis of concurrent vs sequential administration of anti-pd-1 following thoracic radiotherapy: Impact on lung tissue damage","volume":"23","author":"Yan","year":"2025","journal-title":"Dose-Response A Publ Int Hormesis Soc"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.10.01","article-title":"Evaluation of combined anti-pd-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis","volume":"10","author":"Nichols","year":"2018","journal-title":"J Thorac Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.06.2452","article-title":"Decreased survival after combining thoracic irradiation and an anti-pd-1 antibody correlated with increased t-cell infiltration into cardiac and lung tissues","volume":"99","author":"Myers","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181a97e17","article-title":"High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin","volume":"4","author":"Arrieta","year":"2009","journal-title":"J Thorac Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-007-1688-z","article-title":"Radiation recall pneumonitis induced by gemcitabine","volume":"183","author":"Schwarte","year":"2007","journal-title":"Strahlentherapie und Onkologie Organ der Deutschen Rontgengesellschaft [et al]"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2015.1080859","article-title":"Pemetrexed and interstitial lung disease","volume":"55","author":"Adhikari","year":"2016","journal-title":"Acta Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020792","article-title":"Molecular and clinical features of egfr-tki-associated lung injury","volume":"22","author":"Ohmori","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1228","article-title":"1103p drug-related pneumonitis induced by osimertinib as first-line treatment for egfr-positive non-small cell lung cancer: a real-world setting","volume":"33","author":"Sato","year":"2022","journal-title":"Ann Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated Egfr-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"Sting-dependent cytosolic dna sensing promotes radiation-induced type i interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4363","article-title":"Safety of thoracic radiotherapy after pd-(l)1 inhibitor treatment in patients with lung cancer","volume":"10","author":"Chen","year":"2021","journal-title":"Cancer Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.10.129","article-title":"Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage iiia-b nsclc: results from the european thoracic oncology platform nicolas phase ii trial (european thoracic oncology platform 6-14)","volume":"16","author":"Peters","year":"2021","journal-title":"J Thorac Oncol Off Publ Int Assoc For Study Lung Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.05.001","article-title":"Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage iii non-small cell lung cancer-the etop nicolas trial","volume":"133","author":"Peters","year":"2019","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage iii non\u2013small cell lung cancer: the phase iii pacific-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.lungcan.2022.02.003","article-title":"Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage iii nsclc: a post-hoc analysis of the pacific trial","volume":"166","author":"Naidoo","year":"2022","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100638","article-title":"Symptomatic pneumonitis with durvalumab after concurrent chemoradiotherapy in unresectable stage iii nsclc","volume":"5","author":"Vansteenkiste","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.09.050","article-title":"Pneumonitis after chemoradiotherapy and adjuvant durvalumab in stage iii non-small cell lung cancer","volume":"118","author":"Edwards","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.03.033","article-title":"Radiation-induced lung injury: assessment and management","volume":"156","author":"Hanania","year":"2019","journal-title":"Chest"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09553002.2025.2531903","article-title":"Advances in noninvasive imaging for detecting radiation-induced lung injury (rili)","volume":"15","author":"Nissen","year":"2025","journal-title":"Int J Radiat Biol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s40001-024-01650-9","article-title":"Dual-energy computed tomography in the early evaluation of acute radiation pneumonia","volume":"29","author":"Wang","year":"2024","journal-title":"Eur J Med Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2026.01.031","article-title":"Prediction of symptomatic radiation pneumonitis in lung cancer patients: a radiomics and dosiomics machine learning approach using the prospective multicenter rtog 0617 and requite trials","volume":"125","author":"Reuter","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.111110","article-title":"Predicting radiation pneumonitis in lung cancer patients using robust 4dct-ventilation and perfusion imaging","volume":"212","author":"Neupane","year":"2025","journal-title":"Radiotherapy Oncol J Eur Soc For Ther Radiol Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110468","article-title":"Mri-based ventilation and perfusion imaging to predict radiation-induced pneumonitis in lung tumor patients at a 0.35t mr-linac","volume":"199","author":"Klaar","year":"2024","journal-title":"Radiotherapy Oncol J Eur Soc For Ther Radiol Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.02.049","article-title":"Quantifying regional radiation-induced lung injury in patients using hyperpolarized (129)xe gas exchange magnetic resonance imaging","volume":"120","author":"Rankine","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06517-5","article-title":"Early, non-invasive detection of radiation-induced lung injury using pet\/ct by targeting cxcr4","volume":"51","author":"Pei","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.11.032","article-title":"Noninvasive quantification of radiation-induced lung injury using a targeted molecular imaging probe","volume":"118","author":"Abston","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B74","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12885-025-15467-0","article-title":"Biomarker study on pneumonitis in durvalumab maintenance therapy after chemoradiotherapy for stage iii non-small cell lung cancer","volume":"26","author":"Yano","year":"2025","journal-title":"BMC Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1667\/rade-25-00013.1","article-title":"Pna-fish-based chromosome aberration frequency and serum il-6 as predictive biomarkers for radiation therapy-induced pneumonitis in lung cancer patients","volume":"204","author":"Loy-Caraos","year":"2025","journal-title":"Radiat Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.92938","article-title":"Detecting biomarkers of radiation pneumonitis in exhaled breath during chemoradiotherapy for stage iii non-small cell lung cancer: results of a prospective feasibility study","volume":"17","author":"Hughes","year":"2025","journal-title":"Cureus"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract11030056","article-title":"Radiation-induced lung injury-current perspectives and management","volume":"11","author":"Rahi","year":"2021","journal-title":"Clinics Pract"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2019180061","article-title":"Recognizing radiation therapy\u2013related complications in the chest","volume":"39","author":"Benveniste","year":"2019","journal-title":"RadioGraphics"},{"key":"B79","doi-asserted-by":"publisher","first-page":"190012","DOI":"10.1183\/16000617.0012-2019","article-title":"Management of pulmonary toxicity associated with immune checkpoint inhibitors","volume":"28","author":"Delaunay","year":"2019","journal-title":"Eur Respir Rev"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.13097","article-title":"Clinical guideline highlights for the hospitalist: management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy","volume":"18","author":"Chitnis","year":"2023","journal-title":"J Hosp Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00515-7","article-title":"Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Hou","year":"2025","journal-title":"Lancet Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.02.030","article-title":"Randomized phase 2 placebo-controlled trial of nintedanib for the treatment of radiation pneumonitis","volume":"116","author":"Rimner","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-007-0006-z","article-title":"Pentoxifylline and alpha-tocopherol in prevention of radiation-induced lung toxicity in patients with lung cancer","volume":"24","author":"Misirlioglu","year":"2007","journal-title":"Med Oncol (Northwood London England)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107822","article-title":"Optimal management of radiation pneumonitis: findings of an international delphi consensus study","volume":"192","author":"Voruganti Maddali","year":"2024","journal-title":"Lung Cancer (Amsterdam Netherlands)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1926641\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:25:04Z","timestamp":1787829904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1926641\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":85,"alternative-id":["10.3389\/fimmu.2026.1926641"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1926641","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1926641"}}